BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma

The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...

December 21, 2023 | News

Advancing Lung Cancer Treatment: Insights from Professor Benjamin Solomon on the ALINA Study and the Future of ALK-Positive NSCLC

In an exclusive BioPharma APAC interview, Professor Benjamin Solomon, a distinguished Medical Oncologist at the Peter MacCallum Cancer Centre, Australia, a...

December 18, 2023 | News

SeekIn and OncoInv Partner to Enhance Global Access to Cancer Detection Tests and Address Disparities in Cancer Care

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced a strategic collaboration with Oncolnv, a fully-owned affil...

December 15, 2023 | News

Singapore Introduces New Treatment for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation

Pierre Fabre Singapore receives approval from the Ministry of Health (“MOH”), Singapore, for the listing of BRAFTOVI on the Cancer Drug L...

December 15, 2023 | News

Virtual twin to improve treatment with cancer immunotherapies

In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surger...

December 14, 2023 | News

Inside the World of Cell Therapies: Illuminating the Future of Cancer Care

The Rise of Cell Therapies in Cancer Care Recent years have witnessed significant strides in the development and application of cell therapies for cancer ...

December 13, 2023 | News

Examining Financial Ruin, Advocating for Change, and Fostering Collaboration in Cancer Care Economics Across the Asia Pacific Region

In a recent email interview with BioPharma APAC, Dr. Nirmala Bhoo-Pathy, a distinguished Professor of (Clinical) Epidemiology at the Faculty of Medicine, U...

December 13, 2023 | News

Combatting Cancer Disparities: Addressing Challenges and Expanding Access to Care in Low- and Middle-Income Countries

In an exclusive email interview with BioPharma APAC, Carmen Auste, the CEO of Cancer Warriors Foundation Philippines and Vice President of Cancer Coalition...

December 13, 2023 | News

First Patient Dosed in U.S. Access Program for Telix's TLX250-CDx Kidney Cancer Imaging

The patient was dosed at ARA Diagnostic Imaging at Austin Radiological Association in Austin (TX, U.S.) following U.S. Food and Drug Administrati...

December 12, 2023 | News

Zhongchao Inc. Partners with Public Health Foundation for Cancer Treatment Advancements

The Project offers free Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi's sarcoma, ovarian cancer...

December 12, 2023 | News

Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced its progression to the second st...

December 12, 2023 | News

CStone's Sugemalimab Granted NMPA Approval for Esophageal Cancer

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy...

December 11, 2023 | News

Regor Reports Positive Results for RGT-419B in Advanced Breast Cancer After CDK4/6 Inhibitor and Endocrine Therapy

RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation s...

December 08, 2023 | News

FDA Prioritizes Review of PADCEV® Combo for Advanced Bladder Cancer

Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progres...

December 04, 2023 | News

Stay Connected